CTLA4 and cancer: Immunotherapy for cancer has entered a new phase since the discovery of therapeutics that can block certain immunological checkpoints, such as the cytotoxic T lymphocyte antigen-4 (CTLA-4) and, more recently, the programmed death-1 receptor (PD1) and its ligand (PDL1).